StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.97−0.53 (-0.55%)

Close on Nov 17, 2026Market cap $10.89BP/E 28.3Yield –

Halozyme Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Halozyme Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 82.4%. For fiscal 2025 it was 83.6%, against 84.3% the year before. The highest annual figure on record is 99.5% in fiscal 2011.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202583.6%−0.7
FY2024Dec 31, 202484.3%+7.5
FY2023Dec 31, 202376.8%−2.1
FY2022Dec 31, 202278.9%−2.7
FY2021Dec 31, 202181.6%−2.2
FY2020Dec 31, 202083.8%+7.0
FY2019Dec 31, 201976.8%−16.6
FY2018Dec 31, 201893.3%+3.2
FY2017Dec 31, 201790.2%+12.8
FY2016Dec 31, 201677.4%−1.0
FY2015Dec 31, 201578.3%+8.5
FY2014Dec 31, 201469.8%−18.8
FY2013Dec 31, 201388.6%−8.8
FY2012Dec 31, 201297.4%−2.1
FY2011Dec 31, 201199.5%+6.8
FY2010Dec 31, 201092.8%−5.0
FY2009Dec 31, 200997.7%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202683.5%−2.2
Q1 FY2026Mar 31, 202679.0%−2.8
Q4 FY2025Dec 31, 202582.6%−3.3
Q3 FY2025Sep 30, 202584.4%+1.4
Q2 FY2025Jun 30, 202585.8%+2.9
Q1 FY2025Mar 31, 202581.7%−3.8
Q4 FY2024Dec 31, 202485.9%+8.6
Q3 FY2024Sep 30, 202483.0%+8.3
Q2 FY2024Jun 30, 202482.9%+5.5
Q1 FY2024Mar 31, 202485.5%+7.2
Q4 FY2023Dec 31, 202377.3%+0.5
Q3 FY2023Sep 30, 202374.6%−2.7
Q2 FY2023Jun 30, 202377.3%−0.4
Q1 FY2023Mar 31, 202378.3%−8.1
Q4 FY2022Dec 31, 202276.8%−2.0
Q3 FY2022Sep 30, 202277.4%−6.6
Q2 FY2022Jun 30, 202277.7%−5.4
Q1 FY2022Mar 31, 202286.4%+6.9
Q4 FY2021Dec 31, 202178.8%+73.8
Q3 FY2021Sep 30, 202184.0%+78.6
Q2 FY2021Jun 30, 202183.1%+82.1
Q1 FY2021Mar 31, 202179.5%+70.2
Q4 FY2020Dec 31, 20205.1%−6.1
Q3 FY2020Sep 30, 20205.3%−9.5
Q2 FY2020Jun 30, 20201.1%−8.8
Q1 FY2020Mar 31, 20209.3%+2.7
Q4 FY2019Dec 31, 201911.2%+2.8
Q3 FY2019Sep 30, 201914.9%−7.2
Q2 FY2019Jun 30, 20199.9%−0.4
Q1 FY2019Mar 31, 20196.6%−5.6
Q4 FY2018Dec 31, 20188.4%+5.7
Q3 FY2018Sep 30, 201822.1%+13.8
Q2 FY2018Jun 30, 201810.4%−4.4
Q1 FY2018Mar 31, 201812.1%−1.0
Q4 FY2017Dec 31, 20172.7%−11.2
Q3 FY2017Sep 30, 20178.2%−4.9
Q2 FY2017Jun 30, 201714.8%–
Q1 FY2017Mar 31, 201713.2%–
Q4 FY2016Dec 31, 201613.9%–
Q3 FY2016Sep 30, 201613.2%–

More Halozyme Therapeutics figures

See a number that looks wrong?